Trials / Completed
CompletedNCT00464776
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
A Randomized, Double-blind, Cross-over, 4-period, 4 Treatment, Within-subject Placebo-controlled Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Type 2 Diabetic Patients With Incipient or Overt Nephropathy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | |
| DRUG | Aliskiren | |
| DRUG | Aliskiren | |
| DRUG | Aliskiren |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-04-01
- First posted
- 2007-04-24
- Last updated
- 2011-02-04
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00464776. Inclusion in this directory is not an endorsement.